about
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cellsAssessment of DNA damage and telomerase activity in exfoliated urinary cells as sensitive and noninvasive biomarkers for early diagnosis of bladder cancer in ex-workers of a rubber tyres industry.Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patientsNew biomarkers to predict the evolution of in situ breast cancersPalbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data.Urine telomerase: an important marker in the diagnosis of bladder cancer.Potential of telomerase expression and activity in cervical specimens as a diagnostic tool.Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case reportPredictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.The current role of telomerase in the diagnosis of bladder cancer.Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT).Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue.Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations.111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance.Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy.Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast.Usefulness of immunological detection of the human telomerase reverse transcriptase.Predictive role of telomerase activity in the clinical outcome of patients with benign lesions of the uterine cervix or CIN.Benefit from anthracyclines in relation to biological profiles in early breast cancer.Biofunctional characteristics of in situ and invasive breast carcinoma.ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA.Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidenceAccuracy of urine telomerase activity to detect bladder cancer in symptomatic patientsUrine Telomerase Activity for the Detection of Bladder Cancer in FemalesRelevance of Urine Telomerase in the Diagnosis of Bladder CancerAre fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer?What to look for in cell-free DNA from breast cancer patientsPetals and thorns in programmed death-ligand 1 testing: Is all non-small cell lung cancer diagnostic material suitable?Detection of HER2 and Topo 2 in breast cancers: comparison between MLPA and FISH approachesCombining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patientsThe Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot StudyCD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expressionEvaluating the appropriateness of chemotherapy in a low-resource cancer centre in sub-Saharan Africa
P50
Q28191591-6C1B14C6-B0E8-4054-8771-04E851EBF617Q33615608-3377D51A-496E-4E7E-A61B-F8CE996634E1Q33842913-D8BF17BF-4811-40A9-BD8F-C9D0844C22A7Q34162165-9152FFDA-79DA-4E79-9816-21A8CED599E8Q34394399-BF929D54-D2E6-4317-B7E3-63E9FE20AFE2Q34472904-FE298682-431E-4529-ABAD-737723345E02Q34770052-BD8063D0-0E73-44DF-B11D-5E81686FDA55Q35588988-F90C8101-47B5-452F-97CB-0C09E42557FDQ35926585-D73CD5CC-3AA7-4301-B001-926307FA90CCQ36116373-466D8E8B-0FC5-470E-A2E2-CFA5DCECF344Q37197686-B1AE8CAF-8386-412E-A148-FFC10FB982E4Q38020241-4E4B586F-3F93-4303-92B8-A7660405D26AQ38573858-2178DE43-F3A9-4D83-9A2A-4399FA56265CQ40393061-2C657B8C-B7FB-4821-99BD-8B2422254BD6Q41015110-810CBD23-4683-4699-A9DD-23A23D637012Q43805944-839A983B-C81C-4739-8536-5B430218E8A5Q43935327-70279C66-B8B3-43CE-94D0-DFC5C7669DFBQ44965550-8A3EF122-9170-4A26-9F29-D531706831E9Q48299134-C5A2BA52-5258-4CBC-B7E3-0B66469A849EQ53058356-83EFC51B-9465-43F6-A004-AF2F006363C5Q53430428-5887988E-0999-499E-ADF6-65653594FA21Q53643067-D25EBAEA-7CDA-4744-9C0C-8B88A5A6517BQ53744184-2EF91E81-029B-44B8-BD74-B38B0A2F2CB4Q54387195-75632AC8-10F3-440E-BFCE-8BD8E16091BBQ54423107-7551793C-D940-4BFE-B5ED-8ADEA175615BQ55065947-396460FF-62FA-492A-A864-830E009C841FQ57107345-786E7070-BFAB-42FB-8230-851C51116A26Q59300401-9DBB5CB1-3832-48B5-8469-9575E97BB0CCQ59300416-97B885D5-8831-416F-8119-FA6134A06CDAQ59300443-5FC311EF-8E33-4EE4-A681-8BC524027C9CQ59308393-C06F6E68-00C7-4E37-BDFF-C61411F0CB67Q59308396-4798939E-B9F0-4E21-8255-2ADD5EF5364CQ59674819-FFE50F91-FA98-42F8-AA1B-97E3E24BD5ACQ59674867-5837F26D-63B1-4F0B-9A2C-17C319C48654Q59674879-5DBE2DDF-6832-433A-99B4-06F3C7C9A401Q59674884-1EDA56EA-FBD4-46B4-ADD1-AB5D996AA9D5Q64079295-9000CEEB-FDE5-43F3-B933-D037BB98D316Q64116663-77EA8E52-F18A-47CC-96DA-18AF2585BCBFQ90700053-C96E4048-ACC9-4826-BB8B-708940F8D214Q91266606-12996387-15FB-4DDA-9866-40A314A40EE5
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sara Bravaccini
@ast
Sara Bravaccini
@en
Sara Bravaccini
@es
Sara Bravaccini
@nl
Sara Bravaccini
@sl
type
label
Sara Bravaccini
@ast
Sara Bravaccini
@en
Sara Bravaccini
@es
Sara Bravaccini
@nl
Sara Bravaccini
@sl
prefLabel
Sara Bravaccini
@ast
Sara Bravaccini
@en
Sara Bravaccini
@es
Sara Bravaccini
@nl
Sara Bravaccini
@sl
P106
P1153
8240989600
P21
P31
P496
0000-0002-0075-8538